Shanghai Pharmaceuticals (601607.SH) has announced that its subsidiary, Shanghai SPH First Biochemical Pharmaceutical Co., Ltd., recently received a Drug Registration Certificate from the National Medical Products Administration for Clevidipine Emulsion Injection, granting approval for the drug's production.

The drug is primarily indicated for the treatment of hypertension in patients who are not suitable for oral therapy or who are expected to respond poorly to oral medication.